Showing 2716 results
-
Press Release /Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC[1] Patients with…
-
Press Release /Ultibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the…
-
Press Release /The European Commission approved Lucentis to treat patients for visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular…
-
Press Release /Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care…
-
Press Release /MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone …
-
Press Release /
Novartis lance SMS for Life 2.0 au Nigeria pour aider à améliorer l'accès aux médicaments essentiels
SMS for Life 2.0 est lancé pour la première fois dans l'Etat de Kaduna, troisième région la plus peuplée du Nigeria, en collaboration avec le ministère de la Santé de l'Etat de Kaduna. Ce… -
Press Release /"SMS for Life 2.0" wird zum ersten Mal im Bundesstaat Kaduna, der bevölkerungsreichsten Region Nigerias, in Zusammenarbeit mit dem Gesundheitsministerium von Kaduna eingeführt. Das Programm nutzt…
-
Press Release /Acquisition to add a once-daily oral H4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline Investigational…
-
Press Release /SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health Program uses smartphones and…
-
Press Release /Periodic Fever Syndromes are rare diseases mostly affecting children[1] and cause recurrent and disabling fevers with potentially life-threatening complications[2] Ilaris® (canakinumab) is…